Η XM δεν παρέχει υπηρεσίες σε κατοίκους των Ηνωμένων Πολιτειών Αμερικής.
R
R

Roche


Ειδήσεις

Deutsche Bank upgrades "high growth unicorn" Eli Lilly to 'buy', raises PT

BUZZ-Deutsche Bank upgrades "high growth unicorn" Eli Lilly to 'buy', raises PT ** Brokerage Deutsche Bank upgrades Eli Lilly LLY.N to 'buy' from 'hold', raises PT to $1,025 from $725 ** Calls the drugmaker a "high growth unicorn", says big beat-and-raise quarter helped settle some nerves ** Says sales of its diabetes drug Mounjaro outside US will create a large revenue base and drive growth ** Lilly plans to launch 2.5 milligrams and 5 mg single-dose vials of its weight-loss drug, Zepbound, in
R

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

Biotech firm Recursion to buy smaller peer Exscientia for $688 million By Anirban Sen NEW YORK, Aug 8 (Reuters) - Recursion Pharmaceuticals RXRX.O , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia EXAI.O for $688 million in an all-stock deal, according to a statement seen by Reuters.
B
N
R
S

Europe's STOXX 600 jumps 1% on banks-led recovery; Novo Nordisk slumps

UPDATE 2-Europe's STOXX 600 jumps 1% on banks-led recovery; Novo Nordisk slumps For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Novo Nordisk logs steepest decline since Aug 2022 Puma slumps after narrowing FY profit outlook Continental up after Q2 results beat Just Eat Takeaway top STOXX 600 gainer after rating upgrade Roche considering divesting $1.9 bln cancer data startup- FT STOXX 600 up 1.5% Updated at 1550 GMT By Ankika Biswas and
B
C
J
P
R
A
E
F
S
U
G

Green shoots for stocks

LIVE MARKETS-Green shoots for stocks Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com . GREEN SHOOTS FOR STOCKS European stocks are set for a positive start to Wednesday after jittery investors were reassured after The Bank of Japan's deputy governor played down the chance of a near-term interest rate hike.
H
L
R
E
F
G

Swiss stocks - Factors to watch on August 7

Swiss stocks - Factors to watch on August 7 ZURICH/GDANSK, Aug 7(Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday: COMPANY STATEMENTS ROCHE HOLDING ROG.S Roche considering divesting $1.9 bln cancer data startup, FT reports. LOGITECH INTERNATIONAL LOGN.S Matteo Anversa to join Logitech as CFO. ECONOMY Swiss July Forex Reserves due at 0700 GMT.
L
R

Roche considering divesting $1.9 bln cancer data startup, FT reports

UPDATE 3-Roche considering divesting $1.9 bln cancer data startup, FT reports Adds details from FT report in paragraphs 4-5 and Citi response in paragraph 7 Aug 7 (Reuters) - Swiss pharmaceutical company Roche ROG.S is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter.
C
G
R

Roche considering divesting $1.9 bln cancer data startup, FT reports

Roche considering divesting $1.9 bln cancer data startup, FT reports Aug 7 (Reuters) - Swiss pharmaceutical company Roche ROG.S is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter. Roche had paid $1.9 billion for New-York based Flatiron Health in 2018. Re
R

Sangamo Therapeutics rises on licensing agreement with Genentech

BUZZ-Sangamo Therapeutics rises on licensing agreement with Genentech ** Shares of gene therapy developer Sangamo Therapeutics SGMO.O surge 60.83% to $1.23 ** Co says it has entered into a license agreement with Roche's ROG.S Genentech to develop therapies for neurodegenerative diseases ** Sangamo has granted Genentech an exclusive license to Sanga
R

Arkema, Man Group, Shell

EUROPE RESEARCH ROUNDUP- Arkema, Man Group, Shell Aug 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Arkema, Man Group and Shell, on Friday. HIGHLIGHTS * Arkema SA AKE.PA : HSBC raises target price to EUR 105 from EUR 103 * Berkeley Group BKGH.L : Jefferies raises target price to 4,936p from 4,834p * Diageo Plc DGE.L : Morgan Stanley cuts target price to 2200p from 2380p * Man Group Plc EMG.L : Peel Hunt cuts to add from buy * Sh
A
A
A
A
A
B
B
B
B
B
C
C
C
D
E
E
M
R
S
S
U
A
B
T

Regeneron beats quarterly results on strong demand for eczema, eye treatments

Regeneron beats quarterly results on strong demand for eczema, eye treatments Aug 1 (Reuters) - Drugmaker Regeneron Pharmaceuticals REGN.O exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs. The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs.
B
R
R
S

BofA sees buying opportunity in Novo amid recent pullback

BUZZ-BofA sees buying opportunity in Novo amid recent pullback ** BofA Global Research sees "macroeconomic pullback" as a buying opportunity for investors in Novo Nordisk NOVOb.CO , confirming its "buy" rating on the obesity drugs maker ** It notes the Danish pharma giant's shares have fallen about 15% since highs in July , while it sees growth cat
R

European Commission Approves Roche’S Vabysmo For Treatment Of RVO

BRIEF-European Commission Approves Roche’S Vabysmo For Treatment Of RVO July 30 (Reuters) - ROCHE HOLDING AG ROG.S : EUROPEAN COMMISSION APPROVES ROCHE’S VABYSMO FOR TREATMENT OF RETINAL VEIN OCCLUSION (RVO) VABYSMO IS ALREADY APPROVED IN SEVERAL COUNTRIES, INCLUDING US AND JAPAN ADDITIONAL SUBMITTED DATA SHOWS THAT UP TO 60% OF PEOPLE RECEIVIN
R

Roche Holding AG Says Fast-Tracking Clinical Development Of Obesity Portfolio - Spokesperson

BRIEF-Roche Holding AG Says Fast-Tracking Clinical Development Of Obesity Portfolio - Spokesperson July 29 (Reuters) - Roche Holding AG ROG.S : ROCHE HOLDING AG - FAST-TRACKING CLINICAL DEVELOPMENT OF OBESITY PORTFOLIO - SPOKESPERSON ROCHE HOLDING AG - CT-996 WILL BE MOVING TOWARDS PHASE 2 TRIALS NEXT YEAR - SPOKESPERSON ROCHE HOLDING AG - AIM TO B
R

Roche Closes Acquisition Of Lumiradx’S Point Of Care Technology

BRIEF-Roche Closes Acquisition Of Lumiradx’S Point Of Care Technology July 29 (Reuters) - ROCHE HOLDING AG ROG.S : ROCHE CLOSES ACQUISITION OF LUMIRADX’S POINT OF CARE TECHNOLOGY TO EXPAND ACCESS TO DIAGNOSTIC TESTING IN PRIMARY CARE Source text for Eikon: ID:nGNEb5BzHp Further company coverage: ROG.S (Gdansk Newsroom)
R

Roche to fast-track weight loss drugs to compete with rivals, FT reports

UPDATE 1-Roche to fast-track weight loss drugs to compete with rivals, FT reports Adds details from FT report throughout; background in paragraphs 2 and 4 July 29 (Reuters) - Swiss drugmaker Roche ROG.S plans to accelerate the development of its anti-obesity drugs to challenge rivals like Eli Lilly LLY.N and Novo Nordisk NOVOb.CO in the booming market, the Financial Times reported on Monday.
R

Swiss stocks - Factors to watch on July 29

Swiss stocks - Factors to watch on July 29 ZURICH/GDANSK, July 29 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: COMPANY STATEMENTS ROCHE HOLDING ROG.S Roche plans to fast-track weight loss pill to compete with rivals, FT reports. ANALYSTS' VIEWS HOLCIM AG HOLN.S - Jefferies raises target price to CHF 85.5 from CHF 84 ECONOMY SNB data on Swiss sight deposits due at 0800 GMT.
R

Roche To Fast-Track Weight Loss Pill To Compete With Rivals - FT

BRIEF-Roche To Fast-Track Weight Loss Pill To Compete With Rivals - FT July 29 (Reuters) - ROCHE TO FAST-TRACK WEIGHT LOSS PILL TO COMPETE WITH RIVALS - FT Source text: tinyurl.com/28xkkxtn Further company coverage: ROG.S
R

Roche to fast-track weight loss pill to compete with rivals, FT reports

Roche to fast-track weight loss pill to compete with rivals, FT reports July 29 (Reuters) - Swiss pharmaceutical company Roche ROG.S plans to fast-track its anti-obesity drugs to challenge Eli Lilly LLY.N and Novo Nordisk NOVOb.CO after unveiling promising data for a weight-loss pill, the Financial Times reported on Monday. Thomas Schinecker, CEO o
R

European shares fall as earnings deluge disappoints

UPDATE 2-European shares fall as earnings deluge disappoints STOXX 600 down 0.7% Universal Music Group slumps as streaming growth disappoints Kering down after weak H2 forecast Besi tumbles as Q3 outlook disappoints Unilever gains after H1 profit beat Updated at 1600 GMT By Pranav Kashyap and Shashwat Chauhan July 25 (Reuters) - European shares closed lower on Thursday as a slate of downbeat earnings reports in several sectors including tech and luxury weighed, while a global run for safe haven
K
L
N
R
R
S
A
E
F
U
G

STOXX 600 drops to 12-week low as earnings fail to impress

LIVE MARKETS-STOXX 600 drops to 12-week low as earnings fail to impress STOXX 600 down 1.2% CAC 40 hits lowest since Jan UMG tumbles after results European semis weak Healthcare shines Wall St futures steady Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com STOXX 600 DROPS TO 12-WEEK LOW AS EARNINGS FAIL TO IMPRESS European equities are in the red on Thursday as the decline in glob
A
R
S
V
E
F
U
G



Όροι

Δημοφιλή περιουσιακά στοιχεία

Δήλωση αποποίησης ευθύνης: Οι οντότητες του ομίλου XM Group παρέχουν υπηρεσίες σε βάση εκτέλεσης μόνο και η πρόσβαση στην ηλεκτρονική πλατφόρμα συναλλαγών μας που επιτρέπει στον ενδιαφερόμενο να δει ή/και να χρησιμοποιήσει το περιεχόμενο που είναι διαθέσιμο στην ιστοσελίδα μας ή μέσω αυτής, δε διαφοροποιεί ούτε επεκτείνει αυτές τις υπηρεσίες πέραν αυτού ούτε προορίζεται για κάτι τέτοιο. Η εν λόγω πρόσβαση και χρήση υπόκεινται σε: (i) Όρους και προϋποθέσεις, (ii) Προειδοποιήσεις κινδύνου και (iii) Πλήρη δήλωση αποποίησης ευθύνης. Ως εκ τούτου, το περιεχόμενο αυτό παρέχεται μόνο ως γενική πληροφόρηση. Λάβετε ιδιαιτέρως υπόψη σας ότι τα περιεχόμενα της ηλεκτρονικής πλατφόρμας συναλλαγών μας δεν αποτελούν παρότρυνση, ούτε προσφορά για να προβείτε σε οποιεσδήποτε συναλλαγές στις χρηματοπιστωτικές αγορές. Η πραγματοποίηση συναλλαγών στις χρηματοπιστωτικές αγορές ενέχει σημαντικό κίνδυνο για το κεφάλαιό σας.

Όλο το υλικό που δημοσιεύεται στην ηλεκτρονική πλατφόρμα συναλλαγών μας προορίζεται για εκπαιδευτικούς/ενημερωτικούς σκοπούς μόνο και δεν περιέχει, ούτε θα πρέπει να θεωρηθεί ότι περιέχει συμβουλές και συστάσεις χρηματοοικονομικές ή σε σχέση με φόρο επενδύσεων και την πραγματοποίηση συναλλαγών, ούτε αρχείο των τιμών διαπραγμάτευσής μας ούτε και προσφορά ή παρότρυνση για συναλλαγή οποιωνδήποτε χρηματοπιστωτικών μέσων ή ανεπιθύμητες προς εσάς προωθητικές ενέργειες.

Οποιοδήποτε περιεχόμενο τρίτων, καθώς και περιεχόμενο που εκπονείται από την ΧΜ, όπως απόψεις, ειδήσεις, έρευνα, αναλύσεις, τιμές, άλλες πληροφορίες ή σύνδεσμοι προς ιστότοπους τρίτων το οποίο περιέχεται σε αυτήν την ιστοσελίδα παρέχεται «ως έχει», ως γενικός σχολιασμός της αγοράς και δεν αποτελεί επενδυτική συμβουλή. Στον βαθμό που οποιοδήποτε περιεχόμενο ερμηνεύεται ως επενδυτική έρευνα, πρέπει να λάβετε υπόψη και να αποδεχτείτε ότι το περιεχόμενο δεν προοριζόταν και δεν έχει προετοιμαστεί σύμφωνα με τις νομικές απαιτήσεις που αποσκοπούν στην προώθηση της ανεξαρτησίας της επενδυτικής έρευνας και ως εκ τούτου, θα πρέπει να θεωρηθεί ως επικοινωνία μάρκετινγκ σύμφωνα με τους σχετικούς νόμους και κανονισμούς. Παρακαλούμε εξασφαλίστε ότι έχετε διαβάσει και κατανοήσει τη Γνωστοποίησή μας περί Μη ανεξάρτητης επενδυτικής έρευνας και την Προειδοποίηση ρίσκου όσον αφορά τις παραπάνω πληροφορίες, τις οποίες μπορείτε να βρείτε εδώ.

Προειδοποίηση ρίσκου: Τα κεφάλαιά σας κινδυνεύουν. Τα προϊόντα με μόχλευση ενδέχεται να μην είναι κατάλληλα για όλους. Παρακαλούμε λάβετε υπόψη σας τη Γνωστοποίηση ρίσκου.